Interestingly, breast cancer patients undergoing anti-PD-1/PD-L1 therapy have exhibited elevated expression of TIC-associated markers post-treatment, reflecting the findings observed in the in vivo mouse models [70]. This evidence concerns the gene PDCD1 and breast cancer.